A Study of RSLV-132 in Females With Sjögren's Disease
Conditions
Primary Sjögren Syndrome
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Resolve Clinical Site, Chula Vista, California, United States
Resolve Clinical Site, Tustin, California, United States
Resolve Clinical Site, Boca Raton, Florida, United States
Resolve Clinical Site, Boynton Beach, Florida, United States
Evolution Research Center, Hialeah, Florida, United States
GNP Research, Hollywood, Florida, United States
Resolve Clinical Site, Miami, Florida, United States
Life Medical Research, Miami Gardens, Florida, United States
Resolve Clinical Site, Chicago, Illinois, United States
University of Iowa, Iowa City, Iowa, United States
Tufts College, Boston, Massachusetts, United States
Resolve Clinical Site, Albuquerque, New Mexico, United States
Joint and Muscle Research Institute, Charlotte, North Carolina, United States
Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina, United States
Onsite Clinical Solutions, Salisbury, North Carolina, United States
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Resolve Clinical Site, Nashville, Tennessee, United States
Resolve Clinical Site, Austin, Texas, United States
Resolve Clinical Site, Katy, Texas, United States
Resolve Clinical Site, McKinney, Texas, United States
Accurate Clinical Research, Richmond, Texas, United States
Resolve Clinical Site, San Antonio, Texas, United States
Metrodora Institute, Salt Lake City, Utah, United States
Arthritis Northwest, Spokane, Washington, United States
Study leads
James Posada
Study Director
Resolve Therapeutics LLC